Endomag is a medical technology company devoted to improving the global standard of cancer care. Our Sentimag® probe, Magseed® marker and Magtrace® lymphatic mapping agent are already in use by many of the world’s leading physicians and cancer centres. Our goal is to help women with breast cancer avoid surgery when it isn’t needed, and experience better outcomes when it is. We’ve helped tens of thousands of women around the world access more precise and less invasive breast cancer care. Founded in 2007 as a spin-out from the University of Houston and the University College London (UCL), we continue to develop our unique clinical platform from our headquarters in Cambridge, United Kingdom.